2,3-Dimethoxyamphetamine (2,3-DMA), also known as DMA-2, is a drug of the phenethylamine and amphetamine families. It is one of the positional isomers of dimethoxyamphetamine.
2,3-DMA does not appear to have been tested in humans.
The drug showed weak affinity for serotonin receptors in rat stomach fundus strips (A2 = 2,880nM). In a subsequent study, 2,3-DMA showed very low affinity for the serotonin 5-HT2A and 5-HT2C receptors (Ki = 4,280nM and >10,000nM, respectively). It did not show activity as a norepinephrine releasing agent in vitro. The drug is behaviorally active in mice. 2,3-DMA did not substitute for DOM in rodent drug discrimination tests. However, it did partially substitute for 5-MeO-DMT in these tests. As with DOM, the drug did not substitute for dextroamphetamine in drug discrimination tests. It produced behavioral disruption at higher doses.
The chemical synthesis of 2,3-DMA has been described.
2,3-DMA was first described in the scientific literature by F. Benington and colleagues by 1968. Alexander Shulgin first described 2,3-DMA in 1969 but had not yet synthesized it and did not report its effects.
See also Dimethoxyamphetamine Substituted methoxyphenethylamine 2,3-Dimethoxyphenethylamine
References
External links 2,3-DMA - Isomer Design 2,3-DMA - The Shulgin Index